Vantage Consulting Group’s Novartis NVS Stock Holding History

Vantage Consulting Group’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-206	Closed	-$19K	–	1073
2020 Q4	$19K	Buy	+206	New	+$18K	﹤0.01%	902

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vantage Consulting Group's NVS Position: Q1 2021 in Review

Vantage Consulting Group sold out of Novartis (NVS) in Q1 2021, closing a stake of 206 shares — an estimated $19K sold.

Vantage Consulting Group first reported a position in NVS in Q4 2020 and held it in 1 quarter. The position peaked at $19K in Q4 2020. 1,135 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

Vantage Consulting Group reported no remaining Novartis position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 206 Novartis shares in Q1 2021, an estimated $19K.
Vantage Consulting Group first reported a position in Novartis in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Novartis position peaked at $19K in Q4 2020.
1,135 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.